B-intervention	0	9	Tamoxifen
O	10	12	as
O	13	21	adjuvant
O	22	27	after
O	28	35	surgery
O	36	39	for
O	40	46	breast
O	47	53	cancer
O	54	57	and
O	58	67	tamoxifen
O	68	70	or
B-control	71	78	placebo
O	79	81	as
O	82	97	chemoprevention
O	98	100	in
O	101	108	healthy
O	109	114	women
O	114	115	:
O	116	125	different
O	126	136	compliance
O	137	141	with
O	142	151	treatment
O	151	152	.

O	153	156	The
O	157	160	aim
O	161	163	of
O	164	168	this
O	169	174	study
O	175	178	was
O	179	181	to
O	182	193	investigate
O	194	201	whether
O	202	211	tamoxifen
O	212	220	toxicity
O	221	224	and
O	225	234	treatment
O	235	251	discontinuations
O	252	260	differed
O	261	263	in
O	264	267	the
O	268	276	adjuvant
O	277	283	versus
O	284	299	chemopreventive
O	300	307	setting
O	307	308	.

O	309	311	At
O	312	315	our
O	316	328	Institutions
B-total-participants	329	332	119
B-eligibility	333	347	postmenopausal
I-eligibility	348	354	breast
I-eligibility	355	361	cancer
I-eligibility	362	370	patients
O	371	375	were
O	376	386	randomized
O	387	391	from
O	392	398	August
O	399	403	1987
O	404	406	to
O	407	412	March
O	413	417	1995
O	418	420	to
O	421	430	tamoxifen
O	431	435	only
O	436	442	within
O	443	451	adjuvant
O	452	459	studies
O	460	461	(
O	461	474	International
O	475	481	Breast
O	482	488	Cancer
O	489	494	Study
O	495	500	Group
O	501	508	studies
O	509	512	VII
O	513	516	and
O	517	519	IX
O	519	520	)
O	521	524	and
O	525	528	202
O	529	536	healthy
O	537	552	hysterectomized
O	553	558	women
O	559	563	aged
B-age	564	566	35
I-age	566	567	-
I-age	567	569	70
I-age	570	575	years
O	576	580	were
O	581	591	randomized
O	592	596	from
O	597	605	November
O	606	610	1993
O	611	613	to
O	614	617	May
O	618	622	1996
O	623	625	in
O	626	627	a
O	628	639	multicenter
O	639	640	,
O	641	647	double
O	647	648	-
O	648	653	blind
O	653	654	,
O	655	662	placebo
O	662	663	-
O	663	673	controlled
O	674	689	chemoprevention
O	690	695	study
O	696	697	(
B-location	697	704	Italian
O	705	714	Tamoxifen
O	715	725	Prevention
O	726	731	Study
O	731	732	)
O	732	733	.

O	734	737	The
O	738	747	tamoxifen
O	748	752	dose
O	753	756	was
O	757	759	20
O	760	762	mg
O	762	763	/
O	763	766	day
O	767	770	for
O	771	772	5
O	773	778	years
O	779	781	in
O	782	785	all
O	786	793	studies
O	793	794	.

O	795	801	Median
O	802	805	age
O	806	809	was
B-age	810	812	66
I-age	813	818	years
I-age	819	820	(
I-age	820	822	54
I-age	822	823	-
I-age	823	825	85
I-age	825	826	)
O	827	829	in
O	830	833	the
O	834	842	adjuvant
O	843	850	studies
O	851	854	and
B-age	855	857	53
I-age	858	863	years
I-age	864	865	(
I-age	865	867	37
I-age	867	868	-
I-age	868	870	69
I-age	870	871	)
O	872	874	in
O	875	878	the
O	879	894	chemoprevention
O	895	900	study
O	900	901	.

O	902	908	Median
O	909	918	treatment
O	919	927	duration
O	928	931	was
O	932	935	238
O	936	939	and
O	940	943	120
O	944	949	weeks
O	949	950	,
O	951	963	respectively
O	963	964	.

O	965	973	Patients
O	974	981	treated
O	982	988	within
O	989	997	adjuvant
O	998	1005	studies
O	1006	1017	experienced
O	1018	1022	more
B-outcome	1023	1026	hot
I-outcome	1027	1034	flashes
O	1034	1035	,
B-outcome	1036	1043	vaginal
I-outcome	1044	1053	discharge
I-outcome	1054	1057	and
I-outcome	1057	1058	/
I-outcome	1058	1060	or
I-outcome	1061	1069	bleeding
O	1069	1070	,
B-outcome	1071	1075	bone
I-outcome	1076	1082	marrow
I-outcome	1083	1093	depression
O	1094	1097	and
B-outcome	1098	1104	weight
I-outcome	1105	1109	gain
O	1110	1114	than
O	1115	1120	those
O	1121	1128	treated
O	1129	1131	in
O	1132	1135	the
O	1136	1151	chemoprevention
O	1152	1157	study
O	1157	1158	,
O	1159	1169	consistent
O	1170	1174	with
O	1175	1178	the
O	1179	1183	fact
O	1184	1188	that
O	1189	1190	a
O	1191	1201	proportion
O	1202	1204	of
O	1205	1210	women
O	1211	1213	in
O	1214	1217	the
O	1218	1224	latter
O	1225	1230	study
O	1231	1235	were
O	1236	1245	receiving
O	1246	1253	placebo
O	1253	1254	.

B-outcome	1255	1264	Temporary
I-outcome	1265	1280	discontinuation
O	1281	1289	occurred
O	1290	1292	in
B-iv-bin-percent	1293	1294	2
I-iv-bin-percent	1294	1295	.
I-iv-bin-percent	1295	1296	5
I-iv-bin-percent	1296	1297	%
O	1298	1300	of
O	1301	1309	patients
O	1310	1312	in
O	1313	1316	the
O	1317	1325	adjuvant
O	1326	1333	studies
O	1334	1337	and
O	1338	1340	in
B-cv-bin-percent	1341	1342	5
I-cv-bin-percent	1342	1343	.
I-cv-bin-percent	1343	1344	4
I-cv-bin-percent	1344	1345	%
O	1346	1348	of
O	1349	1354	women
O	1355	1357	in
O	1358	1361	the
O	1362	1377	chemoprevention
O	1378	1383	study
O	1384	1385	(
O	1385	1395	difference
O	1396	1399	not
O	1400	1413	statistically
O	1414	1425	significant
O	1425	1426	)
O	1426	1427	.

B-outcome	1428	1437	Permanent
I-outcome	1438	1453	discontinuation
O	1454	1457	was
O	1458	1462	more
O	1463	1471	frequent
O	1472	1474	in
O	1475	1478	the
O	1479	1494	chemoprevention
O	1495	1500	study
O	1501	1505	than
O	1506	1508	in
O	1509	1512	the
O	1513	1521	adjuvant
O	1522	1526	ones
O	1527	1528	(
B-cv-bin-percent	1528	1530	26
I-cv-bin-percent	1530	1531	.
I-cv-bin-percent	1531	1532	7
I-cv-bin-percent	1532	1533	%
O	1534	1536	vs
B-iv-bin-percent	1537	1539	15
I-iv-bin-percent	1539	1540	.
I-iv-bin-percent	1540	1541	1
I-iv-bin-percent	1541	1542	%
O	1542	1543	-
O	1543	1544	-
O	1544	1545	P
O	1545	1546	<
O	1547	1548	0
O	1548	1549	.
O	1549	1551	05
O	1551	1552	)
O	1552	1553	.

O	1554	1556	In
O	1557	1564	summary
O	1564	1565	,
O	1566	1569	our
O	1570	1574	data
O	1575	1579	show
O	1580	1584	that
O	1584	1585	,
O	1586	1594	although
O	1595	1598	the
O	1599	1607	toxicity
O	1608	1610	of
O	1611	1620	tamoxifen
O	1621	1623	is
O	1624	1638	superimposable
O	1639	1641	in
O	1642	1645	the
O	1646	1649	two
O	1650	1658	settings
O	1658	1659	,
O	1660	1661	a
O	1662	1668	larger
O	1669	1679	proportion
O	1680	1682	of
O	1683	1688	women
O	1689	1696	treated
O	1697	1699	as
O	1700	1715	chemoprevention
O	1716	1727	discontinue
O	1728	1737	treatment
O	1738	1751	spontaneously
O	1751	1752	.

O	1753	1756	Due
O	1757	1759	to
O	1760	1763	the
O	1764	1770	double
O	1770	1771	-
O	1771	1776	blind
O	1777	1783	nature
O	1784	1786	of
O	1787	1790	the
O	1791	1806	chemoprevention
O	1807	1812	study
O	1812	1813	,
O	1814	1817	the
O	1818	1824	impact
O	1825	1827	of
O	1828	1831	the
O	1832	1840	toxicity
O	1841	1843	of
O	1844	1853	tamoxifen
O	1854	1858	upon
O	1859	1869	compliance
O	1870	1872	in
O	1873	1876	the
O	1877	1892	chemopreventive
O	1893	1900	setting
O	1901	1907	cannot
O	1908	1910	be
O	1911	1922	ascertained
O	1922	1923	.
